0% of IDUs, 3.9% of MSM and NSC 737664 14.6% of heterosexuals and other. Seropositivity for anti-HBc was nearly as frequent as seropositivity for anti-HCV among IDUs, but substantially higher than anti-HCV among MSM (65.3%) and heterosexuals and other (49.6%). Seropositivity for HBsAg was found in 7.2% of IDUs, 8.4% of MSM and 3.2% of heterosexuals and other. Figure 1 Seropositivity for antibodies against hepatitis C virus (anti-HCV), anti-HBc and hepatitis B surface antigen (HbsAg) in control subjects by HIV-transmission category. Swiss HIV Cohort Study, 1984�C2004. IDU: intravenous drug users; MSM: men having … None of the three hepatitis virus markers considered showed an association with NHL risk (Table 2). ORs were 1.05 (95% CI: 0.63�C1.75) for anti-HCV, 0.85 (95% CI: 0.61�C1.18) for anti-HBc and 0.

62 (95% CI: 0.32�C1.20) for HBsAg seropositivity. Table 2 ORs and corresponding 95% CIs for NHL by presence of hepatitis virus markers (Swiss HIV Cohort Study, 1984�C2004) Table 3 shows the influence of anti-HCV seropositivity on NHL risk in separate strata of CD4+ count at enrolment, age, gender and HIV transmission category. Anti-HCV+ PHIV did not show an increased NHL risk compared to anti-HCV? PHIV in any separate stratum except for HIV transmission category, where a significant association between anti-HCV and NHL risk emerged among MSM (OR=2.37; 95% CI: 1.03�C5.43). In no instance, however, was the effect of anti-HCV seropositivity on NHL risk significantly heterogeneous across the strata of the variables considered (Table 3).

Table 3 ORs and corresponding 95% CIs for NHL by presence of anti-HCV in strata of selected matching variables and HIV-transmission category (Swiss HIV Cohort Study, 1984�C2004) Seropositivity for anti-HBc and HBsAg was not associated with NHL risk in any stratum of CD4+ count at enrolment, age, gender or HIV-transmission category (data not shown). Figure 2 shows the percent distribution of CD4+ count at lymphoma diagnosis and NHL subtype separately among anti-HCV+ and anti-HCV? NHL cases. Although 95% CIs always overlapped, a slightly lower proportion of anti-HCV+ than anti-HCV? NHL cases had less than 50 CD4+ cells��l?1 at cancer diagnosis (26.0 vs 35.9%, respectively), or were diagnosed with PBL (19.0 vs 25.8%, respectively). Figure 2 Comparison of percent distribution of CD4+ counts at NHL diagnosis (A) and NHL subtype (B) between 100 anti-HCV+ and 198 anti-HCV? NHL cases.

Swiss HIV Cohort Study, Entinostat 1984�C2004. Anti-HCV: antibodies against hepatitis C virus; … DISCUSSION Seropositivity for HBV and HCV did not increase NHL risk among PHIV in the SHCS. Our findings on HCV, the most studied hepatitis virus in respect to NHL risk (Dal Maso and Franceschi, in press), are consistent with previous studies of PHIV that also did not show an association (Besson et al, 1999; Levine et al, 1999; Waters et al, 2005).